The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 17.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (3 analysts) rates it buy, with a mean price target of $18.
Herbalife Ltd.
HLF · the NYSE · USD · Market cap $1.6B · 8,500 employees
Herbalife Ltd., together with its subsidiaries, provides health and wellness products in North America, Mexico, South and Central America, Europe, the Middle East, Africa, China, and the Asia Pacific.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 08:09 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price15.96 USD at the 13 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 13 Nov 2026
- Our regime readAccumulation, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.22)
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $21.25 to $31.92, base estimate $21.25 (screen dated 2026-11-13).
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.22, read 2026-11-13
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
Herbalife Ltd. holds its Accumulation at $15.96. The statistical read favours the sellers, held for 48 days.
| Phase | Accumulation |
| Quantitative state | The statistical read favours the sellers, held for 48 days |
| Price at the screen | $15.96 |
| Valuation | 8.76 trailing · 4.91 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.72 |
Five Screens, Shown in Full
Does not pass. Debt ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 78.39% | Below 33% | Interest-bearing debt is 78.4% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 15.97% | Below 49% | Money owed to the company is 16.0% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.17% | Below 5% | Only 0.2% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Herbalife's business is in a permissible area, but its interest-bearing debt is about 78% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when HLF's ethical verdict changes
Today HLF does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 13 Nov 2026: it trades at roughly a 25% discount to our $21.25 fair value, 6.00% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. A 24.9% discount to the base estimate.
Third-party analyst targets: 3 covering, consensus Buy. The average target sits +7% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $21.25, with a range of $21.25 to $31.92, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsCheap shakes at a discount but no real edge
Picture a neighbour selling protein shakes door to door in a crowded market. The price tag looks tempting at under twelve dollars a share, yet the business still carries an unknown moat and slim five percent margins even while revenue edges up eight percent. The forward multiple of three point eight times earnings screams value on paper, and the ethical screen clears it without flags.
What stands out is the sheer gap between the current price and our fair value near double that level, backed by a small group of analysts pointing to a twenty one dollar median target. The company moves weight management and wellness products across dozens of markets through direct channels that keep overhead low. That setup explains the low multiple, but it also leaves little room for surprises in execution.
Risk sits in the lack of any durable advantage and the thin profit buffer that could vanish if competition or regulation shifts. Even with the wide discount, the opportunity rating stays at none because the numbers alone do not create conviction. Analysis, not advice.
| Forward P/E | 4.9xfairly priced for its growth rate |
| Trailing P/E | 8.8xvery cheap relative to earnings |
| EPS, trailing | 1.70 |
| EPS, forward | 3.03 |
| Revenue growth | +6.0%slow but positive growth |
| Profit margin | 3.4%barely profitable |
| FCF yield | 21.57% |
| Current ratio | 1.19adequate liquidity, worth monitoring |
| Beta | 0.72steadier than the market |
| Short interest, float | 0.09% |
| 52-week range | 8.50 - 20.40 |
| Market cap | $1.6B |
| Employees | 8,500 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeHLF trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (3 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (3 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (3 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (3 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (3 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (3 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (3 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 3.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (3 analysts) rates it buy, with a mean price target of $18. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 9.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Over the past year the shares are up 37%. Our forward projection puts the odds of a 10% gain over the next month near 30%. The street (3 analysts) rates it buy, with a mean price target of $18.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Is Herbalife (HLF) Still Below Fair Value As Strong Q3 Results Lift Guidance? Yahoo Finance · 4d ago
- Herbalife India and IISc Launch Landmark Study on Healthy Ageing Yahoo Finance · 5d ago
- How Investors Are Reacting To Herbalife (HLF) Raised Sales Guidance Yahoo Finance · 9d ago
- Herbalife to Participate in 1 on 1 Meetings at Stephens Annual Investment Conference on November 19 Yahoo Finance · 10d ago
- Herbalife Ltd (HLF) (Q3 2026) Earnings Call Highlights: Fifth Straight Quarter of Growth, ... Yahoo Finance · 12d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $13.51 | -16.3% | · | $838 | -16.3% |
| 2 months | $15.23 | -25.7% | · | $743 | -25.7% |
| 3 months | $15.22 | -25.7% | · | $743 | -25.7% |
| 6 months | $14.16 | -20.1% | · | $799 | -20.1% |
| 1 year | $8.27 | +36.8% | · | $1,368 | +36.8% |
| 2 years | $11.44 | -1.1% | · | $989 | -1.1% |
| 3 years | $12.02 | -5.9% | · | $941 | -5.9% |
| 5 years | $53.80 | -79.0% | · | $210 | -79.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever HLF does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.